Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin
分子別名(Synonym)
SLAMF7,CD319,CS1,CRACC,19A,FOAP-12
表達區(qū)間及表達系統(tǒng)(Source)
Mouse SLAMF7 Protein, Mouse IgG2a Fc Tag (SL7-M5252) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - Gly 224 (Accession # Q8BHK6-1).
Predicted N-terminus: Ala 22
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 49.4 kDa. The protein migrates as 55-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景(Background)
SLAM家族成員7(SLAMF7)也被稱為CD2樣受體激活細胞毒性細胞(CRACC)、膜蛋白FOAP-12、CD抗原CD319、新型Ly9、蛋白19A,它是一種單程I型膜蛋白,是CD2家族細胞表面受體的成員。SLAMF7在脾臟、淋巴結(jié)、外周血白細胞、骨髓、小腸、胃、闌尾、肺和氣管中表達。SLAMF7的異構(gòu)體1通過SH2D1A非依賴性細胞外信號調(diào)節(jié)ERK介導(dǎo)的途徑介導(dǎo)NK細胞活化。可能在淋巴細胞粘附中起作用。SLAMF7的異構(gòu)體3不介導(dǎo)任何NK細胞活化。
關(guān)鍵字: SLAMF7;SLAMF7蛋白;SLAMF7重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。